LUNG Overview

Pulmonx Corporation is a commercial-stage medical technology company. The Company provides minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The Company’s Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD. The LungTraX Platform is a cloud-based quantitative CT (QCT) analysis service that provides physicians with multiple products, LungTraX Connect, to improve workup efficiency, LungTraX Detect, to enable patient identification and an easy-to-read StratX Lung report that it designed for its solution that includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a proprietary balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation.

Wall Street analysts forecast LUNG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LUNG is4.10 USD with a low forecast of 2.50 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Pulmonx Corp revenue for the last quarter amounts to 22.60M USD, decreased -4.91

Pulmonx Corp. EPS for the last quarter amounts to -0.25 USD, decreased -24.24

Pulmonx Corp (LUNG) has 296 emplpoyees as of March 30 2026.

Today LUNG has the market capitalization of 49.42M USD.